Skip to main content
. 2022 Jun 3;14:35. doi: 10.1186/s11689-022-09446-w

Table 4.

Type of therapeutic response in individuals who responded to therapy

Therapy type All patients (n = 72) Neurodiagnostic study abnormality (n = 29) EEG/MRI/CSF normal (n = 43)
SI% RL% DC% PE% SI% RL% DC% PE% SI% RL% DC% PE%
Antidepressant (n = 45) 46 29 (13/45) 40 (18/45) 34 0 (0/16) 12 (2/16) 25 (4/16) 54 38 (11/29) 48 (14/29)
Antipsychotic (n = 52) 41 33 (17/52) 35 (18/52) 28 0 (0/19) 5 (1/19) 21 (4/19) 49 48 (16/33) 43 (14/33)
Benzodiazepine (n = 63) 57 63 (40/63) 87 (55/63) 41 0 (0/24) 52 (13/25) 72 (18/25) 68 70 (27/39) 95 (37/39)
ECT (n = 49) 65 24 (12/49) 59 (29/49) 32 0 (0/15) 13 (2/15) 40 (6/15) 87 29 (10/34) 68 (23/34)
Nutritional therapy (n = 29) 0 0 (0/29) 0 (0/29) 0 0 (0/13) 0 (0/13) 0 (0/13) 0 0 (0/10) 0 (0/10)

Immunotherapy (n = 43)

Steroids

IVIg

Anti-CD20

MMF/AZ

68

27

73

33

38

48 (58/120)

5 (2/39)

77 (33/43)

58 (11/19)

63 (12/19)

59 (71/120)

26 (10/39)

88 (38/43)

53 (10/19)

68 (13/19)

72

36

82

63

75

47 (9/19)

0 (0/4)

50 (4/8)

67 (2/3)

75 (3/4)

58 (43/74)

8 (2/24)

73 (19/26)

100 (11/11)

85 (11/13)

73 (54/74)

30 (7/24)

96 (25/26)

91 (10/11)

92 (12/13)

45

20

68

0

20

33 (15/46)

0 (0/15)

82 (14/17)

0 (0/8)

17 (1/6)

37 (17/46)

20 (3/15)

76 (13/17)

0 (0/8)

17 (1/6)

Note: Individuals without neurodiagnostic study abnormalities could not display improvement, and thus, only individuals with these findings are reported. Not all patients with neurodiagnostic abnormalities had repeat testing

AZ Azathioprine, CSF cerebrospinal fluid, EEG electroencephalogram, ECT electroconvulsive therapy, DC discontinuation of medication, MRI magnetic resonance imaging, MMF mycophenolate mofetil, PE physical or neurologic examination improvement, RL resolution of lab or neurodiagnostic abnormality, SI% subjective improvement percentage